A study of the safety and efficacy of an experimental drug for the treatment of acute attacks in patients with hereditary angioedema

The goal of this study is to evaluate the safety and efficacy of an experimental drug for the treatment of acute attacks in patients with hereditary angioedema. The study will include four visits and last approximately three months.

You may be eligible to participate in this study if you:

• Are 12 years of age or older
• Have a diagnosis of hereditary angioedema

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.